INTRODUCTION
The problem of resistance to sulfonamide therapy1 in male gonorrhea is well known. Cox (1) states that, in varying degrees, clinical resistance is found in approximately 25 per cent of cases treated with sulfadiazine or sulfathiazole. More recently, the incidence of resistance has risen to approximately 50 per cent of cases admitted to the Boston Dispensary (2) . This resistance is manifested either by persistence of symptoms or by persistence of positive cultures in asymptomatic carriers. Since gonorrhea is usually a self-limited disease, Cox emphasizes the importance of considering all cases as drug failures which do not clear up within 2 weeks after starting sulfonamide therapy. It is likewise important to recognize relapse after apparent cure as a manifestation of resistance, which is often missed in the clinic unless patients are followed every few days by smear, culture, and symptomatology for at least 4 weeks.
Petro (3) summarizes the factors in sulfonamide resistance, emphasizing (1) factors interfering with the transport of drug to the site of infection in adequate dosage, (2) factors interfering with proper drainage of the products of inflammation, (3) factors within the invading organism, and (4) factors within the host and its bodily defenses.
Determination of factors within the gonococcus responsible for this clinical resistance is a logical initial approach. To this end, correlation of the clinical course with laboratory observations on the growth characteristics of the organisms isolated from individual cases in the presence of sulfonamides has been reported by Cohn et al. (4) , 1Sulfanilamide and sulfapyridine are no longer commonly used in the therapy of gonorrhea; in this paper, "sulfonamide therapy" refers to the-use of sulfathiazole, sulfadiazine, or sulfamerizine therapy-these being the newer and more effective drugs.
Bang and Bang (5) , Petro (3) , and, most recently, by Lankford et al. (6) The control plate showed an average of 50 colonies in the inoculum from the sixth dilution of organisms (conc. 10-6).
Since such quantitation of the number of organisms in each suspension was easily repeatable by the method of standardization used, it was possible to express the results of sulfonamide inhibition in vitro as the product of two factors, both essential in estimating resistance to the drugs:
(1) The concentration of drug in the medium, and (2) the concentration of viable organisms inoculated.
In vitro results were reported in two ways (Tables I  and II Table  I and Figure 3 ). Group I, consisting of 18 patients, showed negative smears and cultures, and were asymptomatic on the first examination after therapy was started, remaining negative at each subsequent follow-up examination. This first examination was usually made 24 to 48 hours after sulfonamide was initially administered, as shown in Table I , but in some cases, the first visit was made 3, 5, or 6 days after the beginning of treatment. All of the strains isolated from this group showed Resistance Indices of 5 to 9 with sulfathiazole and 5 to 10 with sulfadiazine. They grew out at most to only the third dilution of organisms inoculated on the plates containing the lowest concentration of each drug, 1 mgm. per cent.
Group II, consisting of 12 patients, continued to show evidence of infection for 26 days or more; in other words, by Cox's criteria, they were true sulfonamide failures. Four of these cases had cultures taken for study before any sulfonamides were given, 4 were previous drug failures before admission to the clinic, and 4 were cultured at varying times after unsuccessful sulfonamide therapy in the dispensary. All 4 Landy dt at. (10) and Stokinger, Charles, and Carpenter (11) have also induced sulfonamide resistance in vitro in formerly responsive strains. They identified an increase in the production of p-amino benzoic acid by the organisms with the acquisition of resistance, and offer this as a partial tentative explanation of the changes in metabolism involved.
possible that other mutants with further variations in sulfonamide resistance also exist. It must be remembered, however, that as yet no demonstration has been made of a responsive strain becoming resistant in vivo under the influence of sulfonamide therapy in gonorrhea. Such a phenomenon has been demonstrated in cases of streptococcus viridans (12) , pneumococcus endocarditis (13) , and pneumococcus pneumonia (14) . (3) Regardless of the stage of the disease at which treatment is begun, sulfonamides seem to act promptly or not at all, leaving the course of a resistant infection unchanged as far as we can tell. This fact is obvious from Table I in the column marked: "Days after onset when therapy was started." Case 14, for instance, received sulfanilamide for the first 2 weeks without effect and was first admitted to the clinic after 23 days of urethral discharge. He was found to have a positive culture, but to be infected with a strain susceptible in vitro to the more effective sulfonamides. His culture and symptoms became permanently negative within 24 hours of the institution of sulfadiazine therapy.
In other words, it appears that a responsive case will be cured by sulfonamides promptly, no matter how long symptoms have been present, while a resistant case will run its course, no matter how soon or how late the drug is started, or how many courses of sulfonamides are given, in the overwhelming majority of cases.5 ' The rarity of success of a second course of sulfonamides where a first course has failed, as well as the dangers of inducing drug resistance in the host by insufficient dosage, are discussed by Cox (15) , who above all would discourage the indiscriminate use of multiple courses of drug in resistant infections, especially if the organism proves to be drug resistant in vitro as well.
The rare prompt response actually attributable to a subsequent course of chemotherapy in an initially resistant infection, as studied in the Boston Dispensary, usually occurs in already waning infections; these cases usually have persisted for over 4 weeks, with subsidence of acute symptoms, and signs that the natural process of selflimitation of the disease is already underway. Adequate in vitro studies on such cases are not complete yet, but we believe that one of several circumstances may account for the success of a second course of sulfonamides where a first has failed:
(1) Attenuation of the organism may occur in the presence of an increasingly hostile and immune host. Such
The clinical picture of the resistant infections is therefore essentially the same as the disease seen before the days of sulfonamide therapy-in our series, infections lasting from 26 days to many months. In these cases, excluding the rare partially resistant infections, there is no evidence that sulfonamides have any appreciable therapeutic effect, by the criteria of Cox (1) . Within this resistant group it is therefore logical that host factors may well help to determine whether a man will be free from disease within a few weeks or within a matter of months.
The essential fact remains, however, that whether or not the initial and prompt cure with sulfonamides will be obtained at all seems to depend upon a contest between organism and drug in a relatively neutral host.
II. Practical application
In all 32 cases studied, it was possible to predict the clinical course that would follow treatment with sulfonamides. It was found that a "typing" of the organisms into responsive and resistant groups could be obtained with accuracy by the use of one plate containing 1 mgm. per cent of each sulfonamide, indicating that considerable simplification of the method would be possible. (The details of a simplified method have already been worked out and published, and it is now being used routinely in the G. U. clinic of the Boston Dispensary under the direction of Dr. Cox (9) .) Recent work (2) has shown that infections may show marked variations in response depending upon whether sulfathiazole, sulfadiazine, or sulfamerizine is used. These cases are not common, but are brought more forcibly to one's attention by the fact that the variations appear correa change might appear as a decrease in the resistance to sulfonamides of the organism subsequently cultured from the patient. As yet, however, there are no reports of a resistant strain changing to a responsive variant in the host.
(2) A different drug may have been used for the late course, the potency of which was greater against the particular organism involved than that of the original drug. (See discussion, Practical application.) (3) Host immunity may have arisen to the point at which slight aid from previously ineffective sulfonamides will complete the elimination of the infection. It is therefore wholly logical that cases should occasionally appear to be completely resistant to therapy with one drug and later respond perfectly to a second course using another drug which, in this particular infection, happens to be more effective, both clinically and in vitro. Harkness ( (4) Host factors appear to be relatively unimportant, except in those infections in which the course is initially unaffected by drug therapy.
(5) The in vitro resistance of the organism, and hence the clinical response to be expected under sulfonamide therapy, can be accurately estimated by the method outlined.
(6) The clinical value of a simplified modification of this "sulfonamide resistance typing" technique has been presented. It is suggested that such in vitro methods have a possible application in other bacterial infections, placing the use of bacteriostatic drugs on a more rational basis, as well as discouraging the use of futile indescriminate courses of sulfonamides where the organism is obviously resistant.
